# Jazz Pharmaceuticals plc (JAZZ) FY2026 YTD Q2 P&L / Income Statement - Company: Jazz Pharmaceuticals plc (JAZZ) - Period: 2026-01-01 to 2026-06-30 - Filing: Q2 FY2026 10-Q, filed 2026-08-03, accession number 0001232524-26-000045 - Page: https://plicit.ai/financials/jazz/fy2026-ytd-q2-income-statement - Chart image: https://plicit.ai/charts/jazz-fy2026-ytd-q2-income-statement-sankey.png ## Chart details: Revenue by Product and Service (12 categories) Income statement for 2026-01-01 through 2026-06-30. View: Product and service (12 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 2,277,200,000 US dollars - **Total operating expenses**: 1,692,400,000 US dollars - **Income (loss) from operations**: 584,800,000 US dollars - **Other income (expense), net (calculated)**: negative 74,600,000 US dollars - **Income (loss) before income tax expense (benefit) and equity in loss of investees**: 510,200,000 US dollars - **Income tax expense (benefit)**: 24,200,000 US dollars - **Net income (loss)**: 485,900,000 US dollars - **Epidiolex/Epidyolex**: 541,900,000 US dollars - **Zepzelca**: 206,800,000 US dollars - **Rylaze/Enrylaze**: 203,200,000 US dollars - **Defitelio/defibrotide**: 109,400,000 US dollars - **Modeyso**: 89,600,000 US dollars - **Vyxeos**: 58,000,000 US dollars - **Ziihera**: 28,700,000 US dollars - **Other**: 2,700,000 US dollars - **Xywav**: 879,400,000 US dollars - **Xyrem**: 61,700,000 US dollars - **High-sodium oxybate AG royalty revenue**: 78,500,000 US dollars - **Other royalty and contract revenues**: 17,300,000 US dollars - **Cost of product sales (excluding amortization of acquired developed technologies)**: 250,500,000 US dollars - **Selling, general and administrative**: 741,900,000 US dollars - **Research and development**: 403,500,000 US dollars - **Intangible asset amortization**: 342,300,000 US dollars - **Gain on sale of priority review voucher**: negative 122,800,000 US dollars - **Acquired in-process research and development**: 77,000,000 US dollars - **Equity in loss of investees**: negative 100,000 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue minus operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. ## Chart details: Revenue by Product and Service (2 categories) - Page: https://plicit.ai/financials/jazz/fy2026-ytd-q2-income-statement/revenue-by-product-and-service-2-categories - Chart image: https://plicit.ai/charts/jazz-fy2026-ytd-q2-revenue-by-product-and-service-2-categories-sankey.png Income statement for 2026-01-01 through 2026-06-30. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 2,277,200,000 US dollars - **Total operating expenses**: 1,692,400,000 US dollars - **Income (loss) from operations**: 584,800,000 US dollars - **Other income (expense), net (calculated)**: negative 74,600,000 US dollars - **Income (loss) before income tax expense (benefit) and equity in loss of investees**: 510,200,000 US dollars - **Income tax expense (benefit)**: 24,200,000 US dollars - **Net income (loss)**: 485,900,000 US dollars - **Product sales, net**: 2,181,400,000 US dollars - **Royalties and contract revenues**: 95,800,000 US dollars - **Cost of product sales (excluding amortization of acquired developed technologies)**: 250,500,000 US dollars - **Selling, general and administrative**: 741,900,000 US dollars - **Research and development**: 403,500,000 US dollars - **Intangible asset amortization**: 342,300,000 US dollars - **Gain on sale of priority review voucher**: negative 122,800,000 US dollars - **Acquired in-process research and development**: 77,000,000 US dollars - **Equity in loss of investees**: negative 100,000 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue minus operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. ## Chart details: Revenue by Geography - Page: https://plicit.ai/financials/jazz/fy2026-ytd-q2-income-statement/revenue-by-geography - Chart image: https://plicit.ai/charts/jazz-fy2026-ytd-q2-revenue-by-geography-sankey.png Income statement for 2026-01-01 through 2026-06-30. View: Geography. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Total revenues**: 2,277,200,000 US dollars - **Total operating expenses**: 1,692,400,000 US dollars - **Income (loss) from operations**: 584,800,000 US dollars - **Other income (expense), net (calculated)**: negative 74,600,000 US dollars - **Income (loss) before income tax expense (benefit) and equity in loss of investees**: 510,200,000 US dollars - **Income tax expense (benefit)**: 24,200,000 US dollars - **Net income (loss)**: 485,900,000 US dollars - **UNITED STATES**: 2,037,700,000 US dollars - **Europe**: 189,800,000 US dollars - **All other**: 49,700,000 US dollars - **Cost of product sales (excluding amortization of acquired developed technologies)**: 250,500,000 US dollars - **Selling, general and administrative**: 741,900,000 US dollars - **Research and development**: 403,500,000 US dollars - **Intangible asset amortization**: 342,300,000 US dollars - **Gain on sale of priority review voucher**: negative 122,800,000 US dollars - **Acquired in-process research and development**: 77,000,000 US dollars - **Equity in loss of investees**: negative 100,000 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue minus operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.